https://www.thebodypro.com/category/hiv-treatment-strategies/tag/research

The Latest

long road ahead

This Week in HIV Research: Do As We Say, Not As We Do

July 9, 2020: Abysmal HIV testing rates in U.S. ambulatory care settings; STI testing frequency in PrEP users; trends in U.S. PrEP uptake; integrating opioid therapy with HCV care in people who inject drugs.

By Barbara Jungwirth and Myles Helfand
slacklining

This Week in HIV Research: So Many Relative Risks

July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.

By Barbara Jungwirth and Myles Helfand
raising the bar

This Week in HIV Research: Setting a New Bar

June 11, 2020: Diagnosis rates within a year of infection; rates of intentional non-daily PrEP use; neurological development in children of birth parents with HIV; point-of-care urine test to assess tenofovir levels.

By Barbara Jungwirth and Myles Helfand
Lynne Mofenson

After Years of Decline, Perinatal HIV Transmission Has Hit a Plateau. Why?

This researcher has some ideas about what we need to do to address the problem.

By Terri Wilder, M.S.W.
selective focus image of Gilead Truvada for PrEP

This Week in HIV Research: PrEP So White

May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.

By Barbara Jungwirth and Myles Helfand
droplet of blood

This Week in HIV Research: How Dangerous Is Low-Level Viremia?

May 14, 2020: Recurring low-level viremia and morbidity/mortality risk; factors affecting severe bacterial infection in people with HIV; infective endocarditis cases on the rise; high rates of opioid use among U.S. veterans with HIV.

By Barbara Jungwirth and Myles Helfand
data

This Week in HIV Research: There’s No Such Thing as Too Much Data

May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.

By Barbara Jungwirth and Myles Helfand
fast pace of life

This Week in HIV Research: Special Considerations

April 30, 2020: Substance use relapse following opioid therapy for chronic pain; affect of cannabis on blood-brain barrier disruptions; PrEP considerations for adolescents; updated CDC contraceptive recommendations for women at risk for HIV.

By Barbara Jungwirth and Myles Helfand
doctor walking away

This Week in HIV Research: How to Fix Our Dwindling HIV Workforce

April 23, 2020: The corps of front-line care providers with HIV-specific experience is aging and retiring, leaving behind a growing need for quality care. We examine recent research and analysis that both describes that need and offers interventions to meet it.

By Barbara Jungwirth and Myles Helfand
integrase inhibitor

This Week in HIV Research: The Fast-Acting Power of Integrase

April 9, 2020: Rapid efficacy of integrase-based treatment; a potent PrEP ad campaign in Chicago; more frequent STI screening for PrEP users; Ryan White funding fuels critical rural HIV care and services.

By Barbara Jungwirth and Myles Helfand